secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001493152-25-009386
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical reports 28% revenue growth in FY2024; guides FY2025 revenue $126M-$130M
--------------------------------------------------------------------------------

- Revenue $117.3M FY2024, up 28% YoY; Q4 revenue $31.5M, up 12%.
- Net loss FY2024 $16.4M ($0.12/share) vs prior year net income $660k (incl $11.7M bargain gain).
- Adjusted EBITDA loss FY2024 $2.3M vs loss $1.4M; Q4 positive $438k vs loss $695k.
- Guidance: FY2025 revenue $126M-$130M (7-11% organic growth); expects free cash flow in H2 2025.
- Post-year-end manufacturing/license deal for SimpliGraft: $1.5M upfront, minimum purchase obligations; annualized cost reductions >$5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315225009386/0001493152-25-009386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315225009386/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer